• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Charles River Laboratories to acquire CRO services division of Galapagos

Charles River Laboratories to acquire CRO services division of Galapagos

March 13, 2014
CenterWatch Staff

Massachusetts-based CRO Charles River Laboratories (CRL) has agreed to acquire the CRO services division of Galapagos, which includes both Argenta and BioFocus, for approximately $179 million.

The businesses offer integrated drug discovery services, with a predominant focus on in vitro capabilities. CRL said the acquisition will position it as a full service, early-stage CRO, with integrated in vitro and in vivo capabilities from target discovery through preclinical development.

The transaction includes future performance payments of up to $7 million.

James C. Foster, chairman, president, and CEO of Charles River, said, “The acquisition of Argenta and BioFocus is precisely in line with our strategy to build a broader portfolio of essential products and services to support the drug discovery and development continuum, and the increasing virtualization of the biopharmaceutical industry. Argenta and BioFocus’ upstream in vitro capabilities will be an excellent fit with our in vivo expertise, and will enable us to engage with our clients earlier in the drug discovery process. This enhances the value we can provide to our clients because it allows them to outsource integrated drug discovery and early-stage development programs to a single provider. This acquisition advances Charles River’s position as a market leader in the fast-growing outsourced discovery services market.”

Galapagos previously announced it had put its drug discovery services arm up for sale to provide funding for the clinical development of its internal pipeline. “The hybrid business model has come to a natural end,” said Onno von de Stolpe, Galapagos CEO. “Galapagos now is considering divesting the services division because the pipeline has matured to a level that we should focus on it.”

The services division also includes Fidelta in Croatia, which is not part of the sale to Charles River.

Located in the U.K. and the Netherlands, Argenta and BioFocus, with more than 340 scientists, provide a suite of drug discovery services from target discovery through the delivery of clinic-ready candidates to a broad range of pharmaceutical and biotechnology companies. Their in vitroexpertise includes medicinal chemistry, target discovery and complex in vitro biology, as well as therapeutic area expertise in respiratory, inflammation, oncology and CNS diseases. Biofocus was founded in 1997 and employs 150 scientists delivering preclinical drug candidates in all therapeutic areas. Argenta, founded in 2000, has 160 staff.

David Smith, currently CEO of Galapagos Services, will continue to lead Argenta and BioFocus as corporate vice president, In Vitro Discovery Services.

In 2013, Argenta and BioFocus generated combined sales of $87 million. The sales growth rate for the combined Argenta and BioFocus businesses is expected to be approximately 10% in 2014. The purchase price implies a multiple of approximately 2x 2013 sales and approximately 12x 2013 adjusted EBITDA. The transaction is expected to close early in the second quarter of 2014, and is expected to add approximately 6% to Charles River’s net sales in 2014.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing